Nurix Therapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines. Its 8-K reports furnish quarterly and annual financial results, corporate presentations, clinical-program updates for bexobrutideg and pipeline programs, and other material events tied to research, development and financing activity.
The company’s SEC disclosures also cover its common stock listed on the Nasdaq Global Market, shelf registration and at-the-market equity distribution arrangements, underwritten equity offerings, and use-of-proceeds language tied to clinical development and research programs. Proxy and governance filings document board composition, director appointments, compensation programs, committee assignments and annual stockholder meeting matters.
Nurix Therapeutics, Inc. reported that CFO Hans van Houte exercised three tranches of restricted stock units, converting 10,180 RSUs into the same number of common shares at a $0 exercise price. He then sold 2,845 shares at a weighted average price of $23.3828, within a $23.00–$23.90 range, solely to cover RSU-related tax withholding under a mandatory “sell to cover” arrangement, rather than as discretionary trades.
Nurix Therapeutics, Inc. reported insider activity by Chief Legal Officer Christine Ring on July 30, 2026. Three RSU tranches of 3,750, 2,858, and 3,572 units (total 10,180) vested and converted into the same number of common shares at a $0.00 exercise price. On the same date, 3,847 common shares were sold at a weighted average price of $23.3828 per share to cover tax withholding obligations through a mandatory “sell to cover” mechanism under the issuer’s equity plans, and the filing notes these were not discretionary trades.
Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen reported the vesting and conversion of 10,180 Restricted Stock Units into an equal number of shares of common stock on July 30, 2026, at an exercise price of $0.00 per share.
On the same date, Hansen sold 3,847 shares of common stock at a weighted average price of $23.3828 per share, within a range of $23.00 to $23.90. According to the disclosure, these shares were sold solely to cover tax withholding obligations under the company’s equity incentive plans through a mandated "sell to cover" transaction and were not discretionary trades.
Nurix Therapeutics reported another period of heavy investment as it advances its protein degradation pipeline, with a net loss of $176.7 million for the six months ended May 31, 2026, compared with $99.8 million a year earlier.
Total revenue fell to $15.3 million from $62.5 million, mainly due to the absence of prior-period license revenue, while research and development spending rose to $171.8 million as clinical programs for bexobrutideg, zelebrudomide and NX‑1607 progressed.
The company ended the quarter with $443.5 million in cash, cash equivalents and marketable securities and 103.7 million shares outstanding. After quarter‑end, Nurix signed a global collaboration with Roche for bexobrutideg, including a $700 million upfront payment and potential milestones bringing total payments up to $2.3 billion.
Nurix Therapeutics reported fiscal second-quarter 2026 results and unveiled a major global collaboration with Roche for its BTK degrader bexobrutideg.
Revenue was $9.0 million for the quarter ended May 31, 2026, down from $44.1 million a year earlier, mainly because the prior period included $30 million of one-time Sanofi license revenue. Research and development expenses rose to $87.7 million, reflecting higher clinical and manufacturing spend, and net loss widened to $89.5 million, or $0.81 per share.
Nurix ended the quarter with $443.5 million in cash, cash equivalents and marketable securities and cites pro-forma cash of about $1.14 billion, including an expected $700 million upfront payment from Roche. The Roche alliance provides potential total payments of up to $2.3 billion tied to bexobrutideg’s development and commercialization.
Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring reported an option exercise-and-sale transaction in company stock. She exercised employee stock options to acquire a total of 11,008 shares of common stock at exercise prices of $8.72 and $1.86 per share, then sold 11,008 shares in an open-market sale at a weighted average price of $23.5616 per share. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan. After these transactions, she directly holds 13,579 shares of common stock and retains an employee stock option covering 128,611 shares at an exercise price of $8.72 per share, expiring on February 12, 2034.
NRIX report: Christine Ring filed a Form 144 to sell 11,008 shares via exercise of stock options and related cash proceeds. The filing also lists prior 10b5-1 sales on ranging from 4/30/2026 to 6/25/2026 totaling multiple transactions with disclosed share counts and gross proceeds.
Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen executed an open-market sale of 5,394 shares of Common Stock at $20.00 per share. The transaction was carried out under a previously adopted Rule 10b5-1 trading plan, indicating it was pre-scheduled rather than timed discretionarily. Following this sale, Hansen holds 115,005 shares directly, so the filing reflects a relatively small, planned reduction in her overall position.
Nurix Therapeutics Chief Legal Officer Christine Ring exercised stock options and sold the resulting shares in a pre-planned trade. On the reported date, she exercised options for 28,935 shares of common stock at strike prices of $8.72 and $7.26 per share and sold 28,935 shares in open-market transactions at a weighted average price of $20.0624 per share, pursuant to a Rule 10b5-1 trading plan. Following these transactions, the filing reports that she holds 13,579 shares of common stock directly and continues to hold employee stock options, including 134,398 options with a $8.72 exercise price expiring in 2034.
Christine Ring reported the resale of 28,935 shares of Common Stock under Rule 144. The filing lists 28,935 shares as securities to be sold via exercise of stock options for cash. The notice also itemizes recent 10b5-1 sales during April–June 2026 with per-trade share counts and proceeds.